JPWO2019234689A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019234689A5 JPWO2019234689A5 JP2020567799A JP2020567799A JPWO2019234689A5 JP WO2019234689 A5 JPWO2019234689 A5 JP WO2019234689A5 JP 2020567799 A JP2020567799 A JP 2020567799A JP 2020567799 A JP2020567799 A JP 2020567799A JP WO2019234689 A5 JPWO2019234689 A5 JP WO2019234689A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- patient
- hydroxyethyl
- ethoxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 59
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 59
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 58
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 38
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 claims description 32
- 208000011580 syndromic disease Diseases 0.000 claims description 30
- 229940100692 oral suspension Drugs 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 23
- 108010016731 PPAR gamma Proteins 0.000 claims description 22
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 22
- 239000000090 biomarker Substances 0.000 claims description 22
- 230000007812 deficiency Effects 0.000 claims description 20
- 208000012268 mitochondrial disease Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 16
- 208000015114 central nervous system disease Diseases 0.000 claims description 12
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 12
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 10
- 201000006938 muscular dystrophy Diseases 0.000 claims description 10
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 10
- 230000036470 plasma concentration Effects 0.000 claims description 9
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 8
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 8
- 206010033799 Paralysis Diseases 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 208000005264 motor neuron disease Diseases 0.000 claims description 8
- 208000021090 palsy Diseases 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 7
- SBHOQYCDAHAMDW-UHFFFAOYSA-N 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 SBHOQYCDAHAMDW-UHFFFAOYSA-N 0.000 claims description 7
- 206010003591 Ataxia Diseases 0.000 claims description 7
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 6
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 208000006443 lactic acidosis Diseases 0.000 claims description 6
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 230000000750 progressive effect Effects 0.000 claims description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims description 4
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims description 4
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 4
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000013234 Pearson syndrome Diseases 0.000 claims description 4
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims description 4
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 4
- 201000007737 Retinal degeneration Diseases 0.000 claims description 4
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003412 degenerative effect Effects 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 230000008774 maternal effect Effects 0.000 claims description 4
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims description 4
- 201000011548 mitochondrial DNA depletion syndrome 4b Diseases 0.000 claims description 4
- 230000002438 mitochondrial effect Effects 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 201000008152 organic acidemia Diseases 0.000 claims description 4
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- FRSYBJDOEMFNDZ-UHFFFAOYSA-N 1-[6-[2-[4-(1,3-thiazolidin-5-ylmethyl)phenoxy]ethyl]pyridin-3-yl]ethanol Chemical compound OC(C)C=1C=CC(=NC=1)CCOC1=CC=C(CC2CNCS2)C=C1 FRSYBJDOEMFNDZ-UHFFFAOYSA-N 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- JXHFHOSKMYEEHT-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.O=C1CSC(=O)N1 JXHFHOSKMYEEHT-UHFFFAOYSA-N 0.000 claims description 2
- 201000002568 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome Diseases 0.000 claims description 2
- 102000011690 Adiponectin Human genes 0.000 claims description 2
- 108010076365 Adiponectin Proteins 0.000 claims description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 claims description 2
- 208000004724 Ataxia neuropathy spectrum Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 206010063292 Brain stem syndrome Diseases 0.000 claims description 2
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 2
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 2
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 claims description 2
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 2
- 102100028675 DNA polymerase subunit gamma-2, mitochondrial Human genes 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010011891 Deafness neurosensory Diseases 0.000 claims description 2
- 101710088194 Dehydrogenase Proteins 0.000 claims description 2
- 208000010772 Dog disease Diseases 0.000 claims description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 2
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 2
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 2
- 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 claims description 2
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 2
- 208000025121 Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome Diseases 0.000 claims description 2
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 2
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 2
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 208000005446 Lupus vulgaris Diseases 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 2
- 208000005647 Mumps Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 208000010316 Myotonia congenita Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 206010029323 Neuromyopathy Diseases 0.000 claims description 2
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 241000206607 Porphyra umbilicalis Species 0.000 claims description 2
- 208000008425 Protein deficiency Diseases 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 2
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims description 2
- 208000033866 Rare inborn errors of metabolism Diseases 0.000 claims description 2
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 2
- 208000012658 Skin autoimmune disease Diseases 0.000 claims description 2
- 208000029033 Spinal Cord disease Diseases 0.000 claims description 2
- 102000046669 Surf-1 Human genes 0.000 claims description 2
- 108060007963 Surf-1 Proteins 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000133 brain stem Anatomy 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 201000011474 congenital myopathy Diseases 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 230000009395 genetic defect Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 230000003274 myotonic effect Effects 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 230000007827 neuronopathy Effects 0.000 claims description 2
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 2
- 210000001328 optic nerve Anatomy 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000006825 purine synthesis Effects 0.000 claims description 2
- 230000006824 pyrimidine synthesis Effects 0.000 claims description 2
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims description 2
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- JHLDJOBIUVJSTG-UHFFFAOYSA-N tdiq Chemical compound C1CNCC2=C1C=C1OCOC1=C2 JHLDJOBIUVJSTG-UHFFFAOYSA-N 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 210000004885 white matter Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 71
- 239000006186 oral dosage form Substances 0.000 claims 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 5
- -1 1-hydroxyethyl 1-hydroxyethyl Chemical group 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382398.8 | 2018-06-06 | ||
| EP18382398 | 2018-06-06 | ||
| PCT/IB2019/054743 WO2019234689A1 (en) | 2018-06-06 | 2019-06-06 | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527045A JP2021527045A (ja) | 2021-10-11 |
| JP2021527045A5 JP2021527045A5 (https=) | 2022-06-14 |
| JPWO2019234689A5 true JPWO2019234689A5 (https=) | 2022-06-14 |
| JP7549344B2 JP7549344B2 (ja) | 2024-09-11 |
Family
ID=62716009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567799A Active JP7549344B2 (ja) | 2018-06-06 | 2019-06-06 | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210308113A1 (https=) |
| EP (1) | EP3801516A1 (https=) |
| JP (1) | JP7549344B2 (https=) |
| KR (1) | KR20210031435A (https=) |
| CN (1) | CN112512524A (https=) |
| AU (1) | AU2019283649A1 (https=) |
| BR (1) | BR112020024917A2 (https=) |
| CA (1) | CA3102407A1 (https=) |
| CL (1) | CL2020003162A1 (https=) |
| EA (1) | EA202092953A1 (https=) |
| IL (1) | IL279183A (https=) |
| MX (1) | MX2020013181A (https=) |
| SG (1) | SG11202012045UA (https=) |
| WO (1) | WO2019234689A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| FI3801515T3 (fi) | 2018-06-06 | 2025-05-27 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| MX2025013233A (es) | 2023-05-09 | 2026-02-03 | Minoryx Therapeutics S L | Formas polimorficas y formulaciones de leriglitazona |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3703058A1 (en) * | 2005-11-29 | 2020-09-02 | Children's Hospital Medical Center | A method of selecting a medication for a patient |
| US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
| EP3125888B1 (en) * | 2014-04-02 | 2018-05-23 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| EP3559010B1 (en) | 2016-12-23 | 2022-06-08 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
-
2019
- 2019-06-06 BR BR112020024917-3A patent/BR112020024917A2/pt not_active Application Discontinuation
- 2019-06-06 MX MX2020013181A patent/MX2020013181A/es unknown
- 2019-06-06 AU AU2019283649A patent/AU2019283649A1/en not_active Abandoned
- 2019-06-06 EA EA202092953A patent/EA202092953A1/ru unknown
- 2019-06-06 WO PCT/IB2019/054743 patent/WO2019234689A1/en not_active Ceased
- 2019-06-06 JP JP2020567799A patent/JP7549344B2/ja active Active
- 2019-06-06 CA CA3102407A patent/CA3102407A1/en active Pending
- 2019-06-06 SG SG11202012045UA patent/SG11202012045UA/en unknown
- 2019-06-06 US US16/972,368 patent/US20210308113A1/en active Pending
- 2019-06-06 CN CN201980046617.8A patent/CN112512524A/zh active Pending
- 2019-06-06 KR KR1020207037943A patent/KR20210031435A/ko not_active Abandoned
- 2019-06-06 EP EP19742912.9A patent/EP3801516A1/en active Pending
-
2020
- 2020-12-03 IL IL279183A patent/IL279183A/en unknown
- 2020-12-04 CL CL2020003162A patent/CL2020003162A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8618154B2 (en) | LXR modulators | |
| JP2021527061A5 (https=) | ||
| CN117285590A (zh) | 一种化合物、其制备方法、包括其的组合物及其应用 | |
| JP2021527045A5 (https=) | ||
| EP2632448B1 (en) | Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods | |
| US20240091210A1 (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| CA2842316A1 (en) | Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)piperidine-2,6-dione | |
| US20180305396A1 (en) | Deuterated compounds | |
| JPWO2019234689A5 (https=) | ||
| EP3760619A1 (en) | Saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound, and pharmaceutical use thereof | |
| JP7549344B2 (ja) | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 | |
| EP1572180B1 (en) | Use of alpha-phenylthiocarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | |
| JPWO2019234690A5 (https=) | ||
| US20250289803A1 (en) | Selective ligands for tau aggregates | |
| US20210346329A1 (en) | Tca cycle intermediates and methods of use thereof | |
| CA3094261C (en) | Compounds for treating cns- and neurodegenerative diseases | |
| JP2019529503A (ja) | 置換フェニルプロピオン酸化合物のエナンチオマー及びその製造方法、、組成物並びに応用 | |
| WO2023183285A1 (en) | Methods of diagnosing and treating neurodegenerative diseases | |
| WO2025059425A1 (en) | Glyt-1 inhibitors and uses thereof | |
| WO2024245371A1 (zh) | 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途 | |
| US20110178100A1 (en) | Apoptosis inhibitor | |
| HK40042762A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| HK1168100B (en) | Lxr modulators | |
| HK1168100A (en) | Lxr modulators | |
| JP2012511544A (ja) | 神経変性疾患もしくは状態または血液疾患もしくは状態、または癌の治療のための三重置換フェナントロリン誘導体 |